Calcineurin Inhibitor–Based versus Cyclophosphamide-Based Immunosuppression for Primary Membranous Nephropathy: A Meta-Analysis of Remission and Relapse
Sriwijaya Journal of Internal Medicine · 09.07.2026 · 4 (1) · 90-104
DOI: 10.59345/sjim.v4i1.277 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Sriwijaya Journal of Internal Medicine, online erschienen am 09.07.2026. Verfasst von Ligat Pribadi Sembiring und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Primary membranous nephropathy (MN) is a leading cause of the nephrotic syndrome in adults. Calcineurin inhibitor (CNI)-based and cyclophosphamide-based regimens are both endorsed as first-line therapy, but their comparative efficacy and the durability of the remission they induce remain uncertain. This study was aimed to compare CNI-based versus cyclophosphamide-based regimens for total remission, complete remission and relapse in adults with primary MN.
Methods
PubMed/MEDLINE, with Scopus and Web of Science indexing checks and manual reference screening, was searched for randomised controlled trials (RCTs) comparing a CNI-based regimen (tacrolimus or cyclosporine) with a cyclophosphamide-based regimen. Risk ratios (RRs) were pooled with a DerSimonian–Laird random-effects model; heterogeneity was quantified with I2. Risk of bias used the Cochrane RoB 2 tool. The review was not registered.
Results
Nine RCTs (eleven articles; 599 participants) were included. Total remission did not differ between strategies (RR 1.02, 95% CI 0.86-1.20; I2=67%; 95% prediction interval 0.61-1.72; CNI 222/297 versus cyclophosphamide 215/302). Complete remission did not differ (RR 0.84, 95% CI 0.34-2.04). Relapse tended to be more frequent after CNI-based therapy (RR 1.76, 95% CI 0.95-3.24; I2=0%) without reaching significance. Estimates were stable across all sensitivity analyses (RR 0.91-1.11) and no small-study effect was detected (Egger p=0.87).
Conclusion
CNI-based and cyclophosphamide-based regimens produced comparable remission in primary MN; a non-significant signal towards more frequent relapse after CNI therapy supports individualised, durability- and toxicity-aware treatment selection.
Zitieren
APA
Sembiring, L. P., & Harun, H. (2026). Calcineurin Inhibitor–Based versus Cyclophosphamide-Based Immunosuppression for Primary Membranous Nephropathy: A Meta-Analysis of Remission and Relapse. Sriwijaya Journal of Internal Medicine, 4(1), 90-104. https://doi.org/10.59345/sjim.v4i1.277
Vancouver
Sembiring LP, Harun H. Calcineurin Inhibitor–Based versus Cyclophosphamide-Based Immunosuppression for Primary Membranous Nephropathy: A Meta-Analysis of Remission and Relapse. Sriwijaya Journal of Internal Medicine. 2026;4(1):90-104. doi:10.59345/sjim.v4i1.277
BibTeX
@article{Sembiring2026,
author = {Sembiring, Ligat Pribadi and Harun, Harnavi},
title = {Calcineurin Inhibitor–Based versus Cyclophosphamide-Based Immunosuppression for Primary Membranous Nephropathy: A Meta-Analysis of Remission and Relapse},
journal = {Sriwijaya Journal of Internal Medicine},
year = {2026},
volume = {4},
number = {1},
pages = {90--104},
doi = {10.59345/sjim.v4i1.277}
}
EUVIMED